YFM Equity Partners led the Series A round to support team expansion and international growth for the software provider.
"SharpCloud are solving a key business problem that large organisations have contended with for many years – ‘how best to use the large quantities of data to inform complex decision making and to shape business strategy?’, removing the need to inform decisions using static slide deck presentations built upon hotchpotch datasets."
Apadmi Ventures has backed the childcare platform to support its expansion into Manchester.
"Tracey’s created a solution to a very real problem – the childcare crisis – and it’s been fantastic to work in partnership with her and the rest of the Student Nannies team. We get a lot of entrepreneurs approach us for investment, but her drive and ambition really stood out to us."
The London technology startup raised the capital from High-Tech Gründerfonds, Kinisis Investment, Sandhutch and George Zarifis.
"Before we started Threedium, everyone felt that 3D technology was expensive, slow-to-load and hard to implement. Threedium have disproved by providing 3D solutions across large and small sized companies and creating activations across eComm sites, Social Media, eRetailers and through ad exchange platforms. Our mission is to continue our approach in democratising 3D web technologies for all brands, agencies and individuals"
The London-based trading platform secured £1.2m from a consortium of business angels to broaden access for novice investors.
"This latest investment marks the next step in our journey to make trading accessible to a younger generation and to dispel the myth that the stock markets are only for the privileged few. We’re incredibly excited to have achieved investment from such a hard-hitting roster of angels."
The financing round was led by Atomico with participation from several returning and new investors.
"The size of this Series B financing, especially this quickly after our Series A round last year, is an endorsement of the value of our platform and the pace at which we have developed. It allows us to scale our impact with the launch of our Rare Treatment Accelerator programme and to progress into clinical trials."